Maravai LifeSciences Holdings, Inc.
MRVI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.08 | -0.16 | 0.10 |
| FCF Yield | 6.69% | -3.78% | -4.61% | -2.72% |
| EV / EBITDA | -14.20 | -14.69 | -14.01 | -73.66 |
| Quality | ||||
| ROIC | 14.53% | -7.42% | -5.46% | -3.95% |
| Gross Margin | 13.58% | 16.39% | 16.49% | 33.62% |
| Cash Conversion Ratio | 0.59 | 0.15 | 0.31 | 0.56 |
| Growth | ||||
| Revenue 3-Year CAGR | -22.90% | -26.51% | -30.41% | -33.54% |
| Free Cash Flow Growth | 311.31% | 10.16% | 30.31% | -561.76% |
| Safety | ||||
| Net Debt / EBITDA | 5.06 | -1.95 | -1.74 | -2.62 |
| Interest Coverage | 16.87 | -9.73 | -7.25 | -3.39 |
| Efficiency | ||||
| Inventory Turnover | 0.79 | 0.85 | 0.79 | 0.75 |
| Cash Conversion Cycle | 142.11 | 132.75 | 147.32 | 153.10 |